Document is current

Any future updates will be listed below

159 Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.159

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark